Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Inherited Metabolic Disease

• Publication date

  2015-04-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10545-015-9844-6PMID 25860819
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria.

  2015cited by this paper
• Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice

  2014cited by this paper
• Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria afte

  2014cited by this paper
• Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone

  2013cited by this paper
• Antioxidant supplements and mortality

  2013cited by this paper
• Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria

  2013cited by this paper
• Recommendations for the management of tyrosinaemia type 1

  2013cited by this paper
• Glutaric acidemia type 1: outcomes before and after expanded newborn screening.

  2012cited by this paper
• Alkaptonuria is a novel human secondary amyloidogenic disease

  2012cited by this paper
• Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC

  2012cited by this paper
• Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.

  2011cited by this paper
• Biochemical and Proteomic Characterization of Alkaptonuric Chondrocytes

  2011cited by this paper
• A quantitative assessment of alkaptonuria

  2011cited by this paper
• A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.

  2011cited by this paper
• Development of an in vitro model to investigate joint ochronosis in alkaptonuria.

  2011cited by this paper
• Neuropsychological outcome of NTBC‐treated patients with tyrosinaemia type 1

  2011cited by this paper
• Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis

  2011cited by this paper
• Proteomic and redox‐proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes

  2010cited by this paper
• Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis.

  2010influential reference
• Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease.

  2010cited by this paper
• Quality of life in noncompliant adults with phenylketonuria after resumption of the diet

  2008cited by this paper
• Antioxidant supplements and mortality.

  2007cited by this paper
• Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis.

  2007cited by this paper
• Modulation of light-induced skin tumors by N-acetylcysteine and/or ascorbic acid in hairless mice.

  2005cited by this paper
• Use of nitisinone in patients with alkaptonuria.

  2005cited by this paper
• Corneal opacities associated with NTBC treatment.

  2002cited by this paper
• Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation.

  2002cited by this paper
• Natural history of alkaptonuria.

  2002cited by this paper
• Outcome of tyrosinaemia type III

  2001cited by this paper
• Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse.

  2000cited by this paper
• The success of dietary protein restriction in alkaptonuria patients is age-dependent

  1998cited by this paper
• Effects of ascorbic acid and low-protein diet in alkaptonuria

  1998cited by this paper
• Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.

  1995cited by this paper
• Intellectual performance of children with maple syrup urine disease

  1993cited by this paper
• Ascorbic acid and alkaptonuria

  1992cited by this paper
• Outcome in tyrosinaemia type II.

  1991cited by this paper
• Effects of Ascorbic Acid in Alkaptonuria: Alterations in Benzoquinone Acetic Acid and an Ontogenic Effect in Infancy

  1989cited by this paper
• Homogentisic acid autoxidation and oxygen radical generation: implications for the etiology of alkaptonuric arthritis.

  1987cited by this paper
• New concepts in the biology and biochemistry of ascorbic acid.

  1986cited by this paper
• Decreased Binding of 14C-Homogentisic Acid induced by Ascorbic Acid in Connective Tissues of Rats with Experimental Alcaptonuria

  1970cited by this paper
• Oxidation of homogentisic acid to ochronotic pigment in connective tissue.

  1969cited by this paper
• Administration of Ascorbic Acid to an Alkaptonuric Patient.∗

  1940cited by this paper

• Alkaptonuria

  2024cites this paper
• Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy

  2023cites this paper
• Dilemmas in the diagnosis and management of osteoporosis in a patient with alkaptonuria: Successful treatment with teriparatide

  2022cites this paper
• Alcaptonuria, ocronosis y artropatía ocronótica

  2022cites this paper
• Adequacy of nitisinone for the management of alkaptonuria

  2022cites this paper
• New insights and advances on pyomelanin production: from microbial synthesis to applications

  2022influential citation
• Case Report: First Documented Hip Arthroplasty on Chinese Patient with Ochronotic Arthropathy

  2022cites this paper
• Alcaptonurie, ochronose et rhumatisme ochronotique

  2022cites this paper
• Alkaptonuria in an adolescent boy

  2021cites this paper
• A mimic of ankylosing spondylitis, ochronosis: case report and review of the literature

  2021cites this paper
• Preventive use of nitisinone in alkaptonuria

  2021cites this paper
• A cross-sectional study

  2021cites this paper
• Asymptomatic Alkaptonuria and Degenerative Disc Herniation Report of Two Rare Cases

  2021cites this paper
• Alkaptonuria: clinical manifestations and an updated approach to treatment of a rare disease

  2021cites this paper
• Rehabilitation seltener Erkrankungen: Ochronose/Alkaptonurie

  2020cites this paper
• Bone health in patients with inborn errors of metabolism

  2018cites this paper
• Alkaptonuria Severity Score Index Revisited: Analysing the AKUSSI and Its Subcomponent Features.

  2018cites this paper
• Musculoskeletal manifestations of alkaptonuria: A case report and literature review

  2018cites this paper
• Medical care of patients with disorders of aromatic amino acid metabolism: a report based on the Polish National Health Fund data records.

  2018cites this paper
• Demographic, Phenotypic and Genotypic Features of Alkaptonuria Patients: A Single Centre Experience

  2018cites this paper
• Misdiagnosis of alkaptonuria in an elderly patient

  2018cites this paper
• Dark Colored Urine in a 2-Year-Old Child.

  2017cites this paper
• Alkaptonuria - An obscure disease

  2016cites this paper
• Inhibition of para‐Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria

  2016cites this paper
• A role for interleukins in ochronosis in a chondrocyte in vitro model of alkaptonuria

  2016cites this paper
• Progress in Alkaptonuria – are we near to an effective therapy?

  2015cites this paper
• Alkaptonuria--first inborn error of metabolism known for a century and new treatment option--preliminary report.

  2015cites this paper
• Rare Osteoarthritis: Ochronosis and Kashin-Beck Disease

  2015cites this paper